P1. Asthma and prescribed β-blockers
Denominator -group at risk Numerator -increased risk identified Has asthma read code dated at least 6 months before audit date and no asthma resolved code since latest asthma code Had a β-blockers prescription within the 6 months leading up to the audit date Practice (ordered by prevalence) Practice (ordered by list size) Overall prevalence: 3.76% Median: 3.60% Interquartile range: 2.69 to 4.62% ICC = 0.031 (0.026 to 0.037) Practices with zero prevalence = 4 (1%)
No of practices with reliability > R (n=523) R=0.7 R=0.8 R=0.9 508 (97%) 498 (95%) 407 (78%)
Practice (ordered by list size) P2. Asthma and prescribed LABA without ICS Denominator -group at risk Numerator -increased risk identified Has asthma read code dated at least 3 months before audit date & prescribed a long-acting beta-2 agonist inhaler (LABA) within the 3 months leading up to the audit date Not prescribed an inhaled corticosteroid (ICS) or a combined LABA-ICS within the 3 months leading up to the audit date Denominator -group at risk Numerator -increased risk identified Has prescription for warfarin between 3 and 6 months before the audit date and again within the 3 months leading up to the audit date Have NOT had a check of their international normalized ratio in the 3 months leading up to the audit date Overall prevalence: 32.3% Median: 9.9% Interquartile range: 2.1 to 87.7% ICC=0.778 (0.753 to 0.802) Practices with zero prevalence =58 (11%)
No of practices with reliability > R (n=521) R=0.7 R=0.8 R=0.9 521 (100%) 521 (100%) 519 (100%)
